Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4133338 | 0.85 | NR1H4 (0.39) | RIPK1PDCD1CD274SLC16A3SLC16A1 | |
| SCHEMBL4119489 | 0.82 | RIPK1 (0.33) | RIPK1SLC16A3SLC16A1MCTS1CYP3A4 | |
| SCHEMBL12425644 | 0.81 | CLCN2 (0.32) | CYP3A4 | |
| SCHEMBL4112431 | 0.77 | RIPK1 (0.36) | RIPK1PDCD1CD274 | |
| SCHEMBL4114627 | 0.74 | PDE5A (0.40) | RIPK1 | |
| SCHEMBL4115198 | 0.74 | RIPK1 (0.37) | RIPK1CYP3A4HTR2C | |
| SCHEMBL4119858 | 0.74 | CNR2 (0.35) | RIPK1PDCD1CD274 | |
| SCHEMBL4127154 | 0.73 | RIPK1 (0.36) | RIPK1PDCD1CD274HTR2C | |
| SCHEMBL2914349 | 0.70 | RIPK1 (0.41) | RIPK1CYP3A4HTR2C | |
| SCHEMBL12425646 | 0.70 | LMNA (0.39) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | RIPK1 3129/4885PDCD1 4671/4885CD274 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.